Engineered t cells take on blood cancers in early trial
NCT ID NCT00709033
First seen Feb 01, 2026 · Last updated May 25, 2026 · Updated 19 times
Summary
This early-phase study tested a new approach for people with advanced B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia (CLL) that had returned or not responded to standard treatments. Researchers took patients' own immune cells (T cells) and added a special receptor (anti-CD19) to help them recognize and attack cancer cells. The goal was to find a safe dose and see how long these modified cells lasted in the body. Only 3 patients took part, so results are very preliminary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.